Skip to main content

Table 4 Hematological, clinical and radiation toxicities per patient (NCI/CTC) (ITT population, n = 70)

From: A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer

  Induction therapy (n =70), n (%) Consolidation therapy (n = 49), n (%)
  All grades Grade 3-4 All grades Grade 3-4
Hematological toxicities per patient     
Anemia 36 (51.4) - 39 (79.6) 2 (4.1)
Neutropenia 31 (44.3) 17 (24.3) 20 (40.8) 1 (2)
Leukopenia 27 (38.6) 6 (8.6) 30 (61.2) 1 (2)
Thrombocytopenia 15 (21.4) - 11 (22.4) -
Febrile neutropenia (Pizzo) 2 (2.85) -
Clinical toxicities (NCI-CTC)     
Fatigue 31 (44.3) 2 (2.9) 23 (46.9) -
Nausea 29 (41.4) 1 (1.4) 15 (30.6) 1 (2)
Vomiting 18 (25.7) 2 (2.9) 10 (20.4) 1 (2)
Diarrhea 11 (15.7) - 5 (10.2) -
Constipation 9 (12.9) - 2 (4.1) -
Anorexia 6 (8.6) - 3 (6.1) 1 (2)
Hypercreatininemia 1 (1.4) - - -
Radiation toxicities     
Esophagitis - - 13 (26.5) -
Skin injury - - 12 (24.5) -
Dysphagia - - 6 (12.2) -
Pain - - 3 (6.1)  
Pulmonary radiation injury - - 1 (2) 1 (2)
Radiation mucositis - - 1 (2) -
Pneumonitis - - 1 (2) -
  1. Acute renal failure observed in 1 patient (G3 at induction).
  2. Acute radiation pneumonitis at 30 days post-completion observed for 1 patient.